Treatment Details – 26.0 months
|Patients: This phase II study involved 49 patients with stage II-III malignant pleural mesothelioma. There were 41 men and 8 women, with a median age of 61 years (ranging from 41-77).|
Treatment: These patients received a surgery (thoractomy or pleurectomy/decortication), the chemotherapy drugs epidoxorubicin, cisplatin, and gemcitabine, the immunotherapy interleukin-2, and radiation.
Toxicity: During the chemotherapy treatment, toxicities included neutropenic fever, alopecia, nausea/vomiting, usuall mild or moderate. Radiation-related toxicity was actinic pneumonia, which was recorded in 38 patients. The IL-2 therapy was associated with mild fever and eosinophilia.
Results: The overall median survival was 26 months. The median survival for patients with stage II disease was 31 months, and for those with stage III disease it was 21 months.
Correspondence: Dr. Marco Lucchi